



## ASX ANNOUNCEMENT

### 1H FY25 Results Reporting Date Notification and Investor Briefing Invitation

**MELBOURNE, Australia (25 February 2025)** – Lumos Diagnostics Holdings Ltd (ASX: LDX, “Lumos” or the “Company”) a leader in rapid, point-of-care diagnostic technologies, will be reporting its 1H FY25 financial results on Thursday, 27 February 2025. An investor briefing has been scheduled for Monday, 3 March 2025 at 1.00pm (AEDT).

During the briefing, Chief Executive Officer, Doug Ward, and Chief Financial Officer, Barrie Lambert will present an overview of the results and discuss recent progress. This will be followed by a Q+A session.

Participants can pre-register ahead of time via the following link:

[https://us02web.zoom.us/webinar/register/WN\\_XK9PWj48RiiwE7vQYWDW1A](https://us02web.zoom.us/webinar/register/WN_XK9PWj48RiiwE7vQYWDW1A)

Once the registration form is completed, investors will receive a confirmation email with details on how to access the briefing. If you would like to ask a question during the briefing, please send your question ahead of the session to: [george.kopsiaftis@irdepartment.com.au](mailto:george.kopsiaftis@irdepartment.com.au).

The Lumos team looks forward to welcoming those shareholders and potential investors who are able to attend.

**-Ends-**

***This announcement has been approved by the Lumos Company Secretary.***

#### **About Lumos Diagnostics**

*Lumos Diagnostics specializes in rapid and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded POC tests that target infectious and inflammatory diseases.*

*For more information visit [lumosdiagnostics.com](https://lumosdiagnostics.com).*

**Forward-Looking Statements**

*This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.*

**Media Contacts:**

Haley Chartres – Australia

HACK Director

[haley@hck.digital](mailto:haley@hck.digital)

+61 423 139 163

**Investor Contact:**

George Kopsiaftis

IR Specialist, IR Department

[ir@lumosdiagnostics.com](mailto:ir@lumosdiagnostics.com)

+61 409 392 687

**Company Registered Office:**

Lumos Diagnostics Holdings Ltd

Level 4, 100 Albert Rd

South Melbourne, VIC 3205, Australia

+61 3 9087 1598